Is JBIO or KALV more undervalued in 2026?

CirclFi compares Jade Biosciences, Inc. (JBIO) and KalVista Pharmaceuticals, Inc. (KALV) using 13 institutional-grade valuation models. JBIO has a Quality of Company score of 4.1/10 while KALV scores 6.3/10.

Which is a better buy — JBIO or KALV?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do JBIO and KALV valuations compare?

JBIO at $20.84 and KALV at $26.77 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

JBIO vs KALV Valuation Comparison 2026 — Intrinsic Value Analysis

JBIO

Biotechnology

Jade Biosciences, Inc.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$20.84

Last close

Models

7/13

Active

KALV

Biotechnology

KalVista Pharmaceuticals, Inc.

Quality

6.3

out of 10

Value Trap

LOW

Price

$26.77

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	JBIO Fair Value	JBIO Upside	KALV Fair Value	KALV Upside
Bayesian DCF	Intrinsic	$5.78	-72.3%	$8.49	-68.3%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.86	-81.5%	$5.03	-81.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for JBIO vs KALV — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

JBIO vs KALV — Which Stock Is More Undervalued?

KALV scores higher with a 6.3/10 quality rating vs JBIO's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Jade Biosciences, Inc. (JBIO) and KalVista Pharmaceuticals, Inc. (KALV) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

JBIO currently trades at $20.84 with a QOC of 4.1/10, while KALV trades at $26.77 with a QOC of 6.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).